JP2007524377A - Ｐｕｆａポリケチドシンターゼ系およびこれらの使用 - Google Patents

Ｐｕｆａポリケチドシンターゼ系およびこれらの使用 Download PDF

Info

Publication number
JP2007524377A
JP2007524377A JP2006509351A JP2006509351A JP2007524377A JP 2007524377 A JP2007524377 A JP 2007524377A JP 2006509351 A JP2006509351 A JP 2006509351A JP 2006509351 A JP2006509351 A JP 2006509351A JP 2007524377 A JP2007524377 A JP 2007524377A
Authority
JP
Japan
Prior art keywords
seq
acid sequence
pufa
domain
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006509351A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007524377A5 (cg-RX-API-DMAC7.html
Inventor
ジェイムズ ジー． メッツ
クレイグ エイ． ウェーバー
ウィリアム アール． バークレー
ジェイムズ エイチ． フラット
Original Assignee
マーテック・バイオサイエンシーズ・コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マーテック・バイオサイエンシーズ・コーポレーション filed Critical マーテック・バイオサイエンシーズ・コーポレーション
Publication of JP2007524377A publication Critical patent/JP2007524377A/ja
Publication of JP2007524377A5 publication Critical patent/JP2007524377A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
    • C12N15/8247—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving modified lipid metabolism, e.g. seed oil composition
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6436—Fatty acid esters
    • C12P7/6445—Glycerides
    • C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
JP2006509351A 2003-03-26 2004-03-26 Ｐｕｆａポリケチドシンターゼ系およびこれらの使用 Withdrawn JP2007524377A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45797903P 2003-03-26 2003-03-26
PCT/US2004/009323 WO2004087879A2 (en) 2003-03-26 2004-03-26 Pufa polyketide synthase systems and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013038130A Division JP5890791B2 (ja) 2003-03-26 2013-02-28 Ｐｕｆａポリケチドシンターゼ系およびこれらの使用

Publications (2)

Publication Number Publication Date
JP2007524377A true JP2007524377A (ja) 2007-08-30
JP2007524377A5 JP2007524377A5 (cg-RX-API-DMAC7.html) 2012-04-12

Family

ID=33131738

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006509351A Withdrawn JP2007524377A (ja) 2003-03-26 2004-03-26 Ｐｕｆａポリケチドシンターゼ系およびこれらの使用
JP2013038130A Expired - Lifetime JP5890791B2 (ja) 2003-03-26 2013-02-28 Ｐｕｆａポリケチドシンターゼ系およびこれらの使用
JP2015185444A Expired - Lifetime JP6134361B2 (ja) 2003-03-26 2015-09-18 Ｐｕｆａポリケチドシンターゼ系およびこれらの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013038130A Expired - Lifetime JP5890791B2 (ja) 2003-03-26 2013-02-28 Ｐｕｆａポリケチドシンターゼ系およびこれらの使用
JP2015185444A Expired - Lifetime JP6134361B2 (ja) 2003-03-26 2015-09-18 Ｐｕｆａポリケチドシンターゼ系およびこれらの使用

Country Status (11)

Country Link
EP (1) EP1623008B1 (cg-RX-API-DMAC7.html)
JP (3) JP2007524377A (cg-RX-API-DMAC7.html)
KR (3) KR101234198B1 (cg-RX-API-DMAC7.html)
CN (1) CN101389213B (cg-RX-API-DMAC7.html)
AU (2) AU2004225485B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0409046A (cg-RX-API-DMAC7.html)
CA (1) CA2520396C (cg-RX-API-DMAC7.html)
ES (1) ES2516641T3 (cg-RX-API-DMAC7.html)
IL (1) IL200625A0 (cg-RX-API-DMAC7.html)
MX (2) MX341785B (cg-RX-API-DMAC7.html)
WO (1) WO2004087879A2 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012520676A (ja) * 2009-03-16 2012-09-10 マーテック バイオサイエンシーズ コーポレーション ラビリンチュラ菌門の微生物におけるタンパク質作製
JP2019514382A (ja) * 2016-05-12 2019-06-06 ディーエスエム アイピー アセッツ ビー．ブイ．Ｄｓｍ Ｉｐ Ａｓｓｅｔｓ Ｂ．Ｖ． 微細藻類中でのオメガ−３多価不飽和脂肪酸産生を増加させる方法
WO2020032261A1 (ja) * 2018-08-10 2020-02-13 協和発酵バイオ株式会社 エイコサペンタエン酸を生産する微生物及びエイコサペンタエン酸の製造法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340742A (en) 1988-09-07 1994-08-23 Omegatech Inc. Process for growing thraustochytrium and schizochytrium using non-chloride salts to produce a microfloral biomass having omega-3-highly unsaturated fatty acids
US6566583B1 (en) 1997-06-04 2003-05-20 Daniel Facciotti Schizochytrium PKS genes
US8003772B2 (en) * 1999-01-14 2011-08-23 Martek Biosciences Corporation Chimeric PUFA polyketide synthase systems and uses thereof
US7217856B2 (en) 1999-01-14 2007-05-15 Martek Biosciences Corporation PUFA polyketide synthase systems and uses thereof
US7247461B2 (en) 1999-01-14 2007-07-24 Martek Biosciences Corporation Nucleic acid molecule encoding ORFA of a PUFA polyketide synthase system and uses thereof
US7211418B2 (en) 1999-01-14 2007-05-01 Martek Biosciences Corporation PUFA polyketide synthase systems and uses thereof
EP1707055A3 (en) 2000-01-28 2009-01-14 Martek Biosciences Corporation Enhanced production of lipids containing polyenoic fatty acids by very high density cultures of eukaryotic microbes in fermentors
BRPI0613295A2 (pt) 2005-07-01 2010-12-28 Martek Biosciences Corp produto oleoso contendo ácido graxo poliinsaturado e usos e produção do mesmo
GB0603160D0 (en) * 2006-02-16 2006-03-29 Rothamsted Res Ltd Nucleic acid
WO2007106903A2 (en) 2006-03-15 2007-09-20 Martek Biosciences Corporation Polyunsaturated fatty acid production in heterologous organisms using pufa polyketide synthase systems
EP2415360A3 (en) * 2006-08-29 2012-02-29 Martek Biosciences Corporation Use of DPA(n-6) oils in infant formula
WO2010101218A1 (ja) * 2009-03-04 2010-09-10 国立大学法人宮崎大学 微生物の脂肪酸合成経路の判別方法及びそれに用いるｐｃｒプライマーセット
ES2717102T3 (es) 2009-03-19 2019-06-19 Dsm Ip Assets Bv Moléculas de ácido nucleico de ácido graso poliinsaturado sintasas, y polipéptidos, composiciones y métodos de preparación y usos de los mismos
EP2614829A1 (en) * 2012-01-11 2013-07-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Mammalian neural plate border stem cells capable of forming neural tube and neural crest cell lineages including central and peripheral neurons
KR101570771B1 (ko) 2013-11-18 2015-11-23 대한민국 고도불포화지방산 생합성을 위한 재조합 벡터 및 이를 이용하여 제작된 형질전환 식물체
JP6682109B2 (ja) * 2015-01-09 2020-04-15 国立大学法人 宮崎大学 ヤブレツボカビ類を用いたリグニン分解活性を有するタンパク質の製造方法
EP3835412A4 (en) * 2018-08-10 2022-05-11 Kyowa Hakko Bio Co., Ltd. POLYUNSATURATED FATTY ACID PRODUCING MICROORGANISM AND PROCESS FOR THE PRODUCTION OF POLYUNSATURATED FATTY ACID

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998055625A1 (en) * 1997-06-04 1998-12-10 Calgene, Llc Production of polyunsaturated fatty acids by expression of polyketide-like synthesis genes in plants
WO2000042195A2 (en) * 1999-01-14 2000-07-20 Omegatech, Inc. Schizochytrium pks genes
WO2002083870A2 (en) * 2001-04-16 2002-10-24 Martek Biosciences Boulder Corporation Pufa polyketide synthase systems and uses thereof
WO2002094861A2 (en) * 2001-05-21 2002-11-28 Ecopia Biosciences Inc. Genes and proteins involved in the biosynthesis of enediyne ring structures

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340742A (en) * 1988-09-07 1994-08-23 Omegatech Inc. Process for growing thraustochytrium and schizochytrium using non-chloride salts to produce a microfloral biomass having omega-3-highly unsaturated fatty acids
US6677145B2 (en) * 1998-09-02 2004-01-13 Abbott Laboratories Elongase genes and uses thereof
US7247461B2 (en) * 1999-01-14 2007-07-24 Martek Biosciences Corporation Nucleic acid molecule encoding ORFA of a PUFA polyketide synthase system and uses thereof
DK1911837T3 (da) * 2000-09-28 2011-08-29 Bioriginal Food & Science Corp FAD5-2 fedtsyredesaturasefamiliemedlem og anvendelser deraf

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998055625A1 (en) * 1997-06-04 1998-12-10 Calgene, Llc Production of polyunsaturated fatty acids by expression of polyketide-like synthesis genes in plants
WO2000042195A2 (en) * 1999-01-14 2000-07-20 Omegatech, Inc. Schizochytrium pks genes
WO2002083870A2 (en) * 2001-04-16 2002-10-24 Martek Biosciences Boulder Corporation Pufa polyketide synthase systems and uses thereof
WO2002094861A2 (en) * 2001-05-21 2002-11-28 Ecopia Biosciences Inc. Genes and proteins involved in the biosynthesis of enediyne ring structures

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012520676A (ja) * 2009-03-16 2012-09-10 マーテック バイオサイエンシーズ コーポレーション ラビリンチュラ菌門の微生物におけるタンパク質作製
US9012616B2 (en) 2009-03-16 2015-04-21 Dsm Ip Assets B.V. Polynucleotide for improving protein production in microorganisms of the phylum labyrinthulomycota
JP2015077140A (ja) * 2009-03-16 2015-04-23 ディーエスエム アイピー アセッツ ビー．ブイ． ラビリンチュラ菌門の微生物におけるタンパク質作製
US9518102B2 (en) 2009-03-16 2016-12-13 Dsm Ip Assets B.V. Polypeptide for improving protein production in microorganisms of the phylum Labyrinthulomycota
JP2016208993A (ja) * 2009-03-16 2016-12-15 ディーエスエム アイピー アセッツ ビー．ブイ． ラビリンチュラ菌門の微生物におけるタンパク質作製
JP2019514382A (ja) * 2016-05-12 2019-06-06 ディーエスエム アイピー アセッツ ビー．ブイ．Ｄｓｍ Ｉｐ Ａｓｓｅｔｓ Ｂ．Ｖ． 微細藻類中でのオメガ−３多価不飽和脂肪酸産生を増加させる方法
US11987819B2 (en) 2016-05-12 2024-05-21 Dsm Ip Assets B.V. Method of increasing omega-3 polyunsaturated fatty acids production in microalgae
WO2020032261A1 (ja) * 2018-08-10 2020-02-13 協和発酵バイオ株式会社 エイコサペンタエン酸を生産する微生物及びエイコサペンタエン酸の製造法
JPWO2020032261A1 (ja) * 2018-08-10 2021-08-10 協和発酵バイオ株式会社 エイコサペンタエン酸を生産する微生物及びエイコサペンタエン酸の製造法
JP2024003202A (ja) * 2018-08-10 2024-01-11 協和発酵バイオ株式会社 エイコサペンタエン酸を生産する微生物及びエイコサペンタエン酸の製造法
JP7678062B2 (ja) 2018-08-10 2025-05-15 協和発酵バイオ株式会社 エイコサペンタエン酸を生産する微生物及びエイコサペンタエン酸の製造法
JP7838921B2 (ja) 2018-08-10 2026-04-01 協和発酵バイオ株式会社 エイコサペンタエン酸を生産する微生物及びエイコサペンタエン酸の製造法

Also Published As

Publication number Publication date
WO2004087879A3 (en) 2008-07-24
JP2016000048A (ja) 2016-01-07
BRPI0409046A (pt) 2006-04-18
JP5890791B2 (ja) 2016-03-22
EP1623008A4 (en) 2009-05-27
JP6134361B2 (ja) 2017-05-24
CN101389213B (zh) 2014-05-28
ES2516641T3 (es) 2014-10-31
CN101389213A (zh) 2009-03-18
AU2008249169B2 (en) 2012-03-15
KR101234198B1 (ko) 2013-02-19
MX341785B (es) 2016-09-01
EP1623008B1 (en) 2014-07-30
JP2013143945A (ja) 2013-07-25
EP1623008A2 (en) 2006-02-08
CA2520396A1 (en) 2004-10-14
KR101234200B1 (ko) 2013-02-19
AU2008249169A1 (en) 2008-12-11
AU2004225485B2 (en) 2008-08-21
HK1088632A1 (en) 2006-11-10
AU2004225485A1 (en) 2004-10-14
WO2004087879A2 (en) 2004-10-14
KR20120097502A (ko) 2012-09-04
KR20120123726A (ko) 2012-11-09
MXPA05010214A (es) 2005-12-14
KR101234199B1 (ko) 2013-02-20
CA2520396C (en) 2016-08-09
IL200625A0 (en) 2011-07-31
KR20060006014A (ko) 2006-01-18

Similar Documents

Publication Publication Date Title
JP6134361B2 (ja) Ｐｕｆａポリケチドシンターゼ系およびこれらの使用
US7211418B2 (en) PUFA polyketide synthase systems and uses thereof
JP2013255497A (ja) Ｐｕｆａポリケチドシンターゼ系およびそれらの使用方法
HK1088632B (en) Pufa polyketide synthase systems and uses thereof
AU2012203480A1 (en) PUFA polyketide synthase systems and uses thereof

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100428

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100722

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100729

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100809

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101028

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110831

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111125

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120221

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20120221

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121031

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20121126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130228

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20130326